source
- Administration releases detailed report on most-favored-nation drug pricing, projects $529 billion savingsThe White House Council of Economic Advisers released its most detailed analysis yet of the administration's most-favored-nation drug pricing policy. The report defines the MFN pricing approach, w…
- Sanofi requests removal of teplizumab from FDA fast-track voucher program after director disputeSanofi has formally asked the Food and Drug Administration to withdraw its type 1 diabetes therapy, teplizumab, from the new speedy review voucher program overseen by Commissioner Marty Makary. Th…